Statistical methods in oncology trials
The methods these trials rely on most, based on the statistical analyses posted to ClinicalTrials.gov, with the tutorial that explains each one.
Hazard ratio
Log-rank test
Cochran-Mantel-Haenszel test
Odds ratio
Cox proportional-hazards model
Fisher exact test
Risk difference
Stratified log-rank test
All oncology trials
2,067 results
- Chemoradiation and Tetrathiomolybdate (TM) in Patients With Esophageal Carcinoma: Complete Statistical AnalysisIndependent statistical analysis of Chemoradiation and Tetrathiomolybdate (TM) in Patients With Esophageal Carcinoma: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT00176800).
- Chemoradiation in Locally Advanced Pancreatic Cancer: Complete Statistical AnalysisIndependent statistical analysis of Chemoradiation in Locally Advanced Pancreatic Cancer: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT00262951).
- Chemoradiation Plus Durvalumab Followed by Surgery Followed by Adjuvant Durvalumab in Patients With Surgically Resectable Stage III (N2) Non-Small Cell Lung Cancer: Complete Statistical AnalysisIndependent statistical analysis of Chemoradiation Plus Durvalumab Followed by Surgery Followed by Adjuvant Durvalumab in Patients With Surgically Resectable Stage III (N2) Non-Small Cell Lung Cancer: primary endpoint results, effect estimate with…
- Chemoradiotherapy in Stage III Non-small Cell Lung Cancer (NSCLC): Complete Statistical AnalysisIndependent statistical analysis of Chemoradiotherapy in Stage III Non-small Cell Lung Cancer (NSCLC): primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT01102231).
- Chemotherapy Administered Every 2 Weeks With or Without Pegfilgrastim in Subjects With Advanced or Metastatic Colon Cancer: Complete Statistical AnalysisIndependent statistical analysis of Chemotherapy Administered Every 2 Weeks With or Without Pegfilgrastim in Subjects With Advanced or Metastatic Colon Cancer: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration,…
- Chemotherapy and Radiation Therapy (RT) With or Without Vandetanib in Treating Patients With High-Risk Stage III or Stage IV Head and Neck Cancer: Complete Statistical AnalysisIndependent statistical analysis of Chemotherapy and Radiation Therapy (RT) With or Without Vandetanib in Treating Patients With High-Risk Stage III or Stage IV Head and Neck Cancer: primary endpoint results, effect estimate…
- Chemotherapy and Radiation Therapy With or Without Panitumumab in Treating Patients With Stage IIIA Non-Small Cell Lung Cancer: Complete Statistical AnalysisIndependent statistical analysis of Chemotherapy and Radiation Therapy With or Without Panitumumab in Treating Patients With Stage IIIA Non-Small Cell Lung Cancer: primary endpoint results, effect estimate with confidence interval, sample-size planning…
- Chemotherapy Before Surgery in Treating Patients With High Grade Upper Urinary Tract Cancer: Complete Statistical AnalysisIndependent statistical analysis of Chemotherapy Before Surgery in Treating Patients With High Grade Upper Urinary Tract Cancer: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on…
- Chemotherapy Followed by Radiation Therapy in Treating Younger Patients With Newly Diagnosed Localized Central Nervous System Germ Cell Tumors: Complete Statistical AnalysisIndependent statistical analysis of Chemotherapy Followed by Radiation Therapy in Treating Younger Patients With Newly Diagnosed Localized Central Nervous System Germ Cell Tumors: primary endpoint results, effect estimate with confidence interval, sample-size…
- Chemotherapy for Patients With Non-Small Cell Lung Cancer Who Are Non-Smokers: Complete Statistical AnalysisIndependent statistical analysis of Chemotherapy for Patients With Non-Small Cell Lung Cancer Who Are Non-Smokers: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results…
- Chemotherapy for Patients With Non-Small Cell Lung Cancer: Complete Statistical AnalysisIndependent statistical analysis of Chemotherapy for Patients With Non-Small Cell Lung Cancer: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT00380718).
- Chemotherapy, Hormone Therapy, and Radiation Therapy in Treating Patients With Locally Advanced Prostate Cancer: Complete Statistical AnalysisIndependent statistical analysis of Chemotherapy, Hormone Therapy, and Radiation Therapy in Treating Patients With Locally Advanced Prostate Cancer: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based…
- Chemotherapy, Radiation Therapy and Immunotherapy Prior to Surgery in Operable Esophageal Cancer: Complete Statistical AnalysisIndependent statistical analysis of Chemotherapy, Radiation Therapy and Immunotherapy Prior to Surgery in Operable Esophageal Cancer: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov…
- Chemotherapy, Radiation Therapy, and Surgery in Treating Patients With Locally Advanced Cancer of the Vulva: Complete Statistical AnalysisIndependent statistical analysis of Chemotherapy, Radiation Therapy, and Surgery in Treating Patients With Locally Advanced Cancer of the Vulva: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety,…
- Chemotherapy, Radiotherapy and Bevacizumab in Patients With Unresectable Stage III Non-Small-Cell Lung Cancer: Complete Statistical AnalysisIndependent statistical analysis of Chemotherapy, Radiotherapy and Bevacizumab in Patients With Unresectable Stage III Non-Small-Cell Lung Cancer: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on…
- Chemotherapy, Stereotactic Body Radiation Therapy & Nelfinavir Mesylate in Locally Advanced Pancreatic Cancer: Complete Statistical AnalysisIndependent statistical analysis of Chemotherapy, Stereotactic Body Radiation Therapy & Nelfinavir Mesylate in Locally Advanced Pancreatic Cancer: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on…
- Chemotherapy, Total Body Irradiation, and Post-Transplant Cyclophosphamide in Reducing Rates of Graft Versus Host Disease in Patients With Hematologic Malignancies Undergoing Donor Stem Cell Transplant: Complete Statistical AnalysisIndependent statistical analysis of Chemotherapy, Total Body Irradiation, and Post-Transplant Cyclophosphamide in Reducing Rates of Graft Versus Host Disease in Patients With Hematologic Malignancies Undergoing Donor Stem Cell Transplant: primary endpoint results,…
- Chloroquine in Combination With VELCADE and Cyclophosphamide for Relapsed and Refractory Multiple Myeloma: Complete Statistical AnalysisIndependent statistical analysis of Chloroquine in Combination With VELCADE and Cyclophosphamide for Relapsed and Refractory Multiple Myeloma: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on…
- Chronic Myelogenous Leukemia or Philadelphia Chromosome Positive Acute Lymphoblastic Leukemic Study: Complete Statistical AnalysisIndependent statistical analysis of Chronic Myelogenous Leukemia or Philadelphia Chromosome Positive Acute Lymphoblastic Leukemic Study: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results…
- CHRYSALISA detailed statistical review of the phase 1 CHRYSALIS study of amivantamab in participants with advanced non-small cell lung cancer, covering trial design, registered endpoints, planned statistical analysis, and interpretation.
- Cilengitide (EMD 121974) for Recurrent Glioblastoma Multiforme (Brain Tumor): Complete Statistical AnalysisIndependent statistical analysis of Cilengitide (EMD 121974) for Recurrent Glioblastoma Multiforme (Brain Tumor): primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT00093964).
- Cilengitide, Temozolomide, and Radiation Therapy in Treating Patients With Newly Diagnosed Glioblastoma Multiforme: Complete Statistical AnalysisIndependent statistical analysis of Cilengitide, Temozolomide, and Radiation Therapy in Treating Patients With Newly Diagnosed Glioblastoma Multiforme: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on…
- Cinnamon Extract on Menstrual Cycles in PolyCystic Ovary Syndrome (PCOS): Complete Statistical AnalysisIndependent statistical analysis of Cinnamon Extract on Menstrual Cycles in PolyCystic Ovary Syndrome (PCOS): primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT01483118).
- CIRCCaIndependent statistical analysis of the CIRCCa phase 2 trial of carboplatin and paclitaxel with or without cediranib maleate in metastatic or recurrent cervical cancer, including trial design, progression-free survival, statistical methodology, and…
- CIRCULATE-USAn independent statistical analysis of CIRCULATE-US (NCT05174169), a randomized phase 2/3 trial evaluating adjuvant chemotherapy strategies based on residual disease assessment in stage III colon cancer.
- Circulating Tumor DNA Testing in Predicting Treatment for Patients With Stage IIA Colon Cancer After Surgery: Complete Statistical AnalysisIndependent statistical analysis of Circulating Tumor DNA Testing in Predicting Treatment for Patients With Stage IIA Colon Cancer After Surgery: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and…
- Cisplatin + Radiation in SCCHN and Correlation With Oxidative Stress Markers: Complete Statistical AnalysisIndependent statistical analysis of Cisplatin + Radiation in SCCHN and Correlation With Oxidative Stress Markers: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results…
- Cisplatin and Flavopiridol in Treating Patients With Advanced Ovarian Epithelial Cancer or Primary Peritoneal Cancer: Complete Statistical AnalysisIndependent statistical analysis of Cisplatin and Flavopiridol in Treating Patients With Advanced Ovarian Epithelial Cancer or Primary Peritoneal Cancer: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety,…
- Cisplatin and Radiation Therapy With or Without Carboplatin and Paclitaxel in Patients With Locally Advanced Cervical Cancer: Complete Statistical AnalysisIndependent statistical analysis of Cisplatin and Radiation Therapy With or Without Carboplatin and Paclitaxel in Patients With Locally Advanced Cervical Cancer: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration,…
- Cisplatin With or Without WEE1 Inhibitor MK-1775 in Treating Patients With Recurrent or Metastatic Head and Neck Cancer: Complete Statistical AnalysisIndependent statistical analysis of Cisplatin With or Without WEE1 Inhibitor MK-1775 in Treating Patients With Recurrent or Metastatic Head and Neck Cancer: primary endpoint results, effect estimate with confidence interval, sample-size planning…
- Cisplatin, Etoposide, and Bevacizumab in Treating Patients With Previously Untreated Extensive Stage Small Cell Lung Cancer: Complete Statistical AnalysisIndependent statistical analysis of Cisplatin, Etoposide, and Bevacizumab in Treating Patients With Previously Untreated Extensive Stage Small Cell Lung Cancer: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and…
- Cisplatin/Carboplatin and Etoposide With or Without Nivolumab in Treating Patients With Extensive Stage Small Cell Lung Cancer: Complete Statistical AnalysisIndependent statistical analysis of Cisplatin/Carboplatin and Etoposide With or Without Nivolumab in Treating Patients With Extensive Stage Small Cell Lung Cancer: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration,…
- Cixutumumab and Temsirolimus in Treating Patients With Locally Recurrent or Metastatic Breast Cancer: Complete Statistical AnalysisIndependent statistical analysis of Cixutumumab and Temsirolimus in Treating Patients With Locally Recurrent or Metastatic Breast Cancer: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on…
- Cixutumumab and Temsirolimus in Treating Patients With Metastatic Prostate Cancer: Complete Statistical AnalysisIndependent statistical analysis of Cixutumumab and Temsirolimus in Treating Patients With Metastatic Prostate Cancer: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT01026623).
- Cladribine With Simultaneous or Delayed Rituximab to Treat Hairy Cell Leukemia: Complete Statistical AnalysisIndependent statistical analysis of Cladribine With Simultaneous or Delayed Rituximab to Treat Hairy Cell Leukemia: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results…
- CLASSICIndependent statistical analysis of the CLASSIC phase 3 trial evaluating capecitabine and oxaliplatin as adjuvant therapy for stomach cancer, including trial design, endpoints, statistical methodology, and interpretation.
- CLEARIndependent statistical analysis of Lenvatinib/Everolimus or Lenvatinib/Pembrolizumab Versus Sunitinib Alone as Treatment of Advanced Renal Cell Carcinoma: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on…
- CLEOPATRAIndependent statistical analysis of CLEOPATRA, the randomized phase 3 trial of pertuzumab plus trastuzumab and docetaxel versus placebo plus trastuzumab and docetaxel in previously untreated HER2-positive metastatic breast cancer.
- Clinical Study to Evaluate CryoBalloon™ Full and Swipe Ablation Systems for Ablation of Human Esophageal Epithelium: Complete Statistical AnalysisIndependent statistical analysis of Clinical Study to Evaluate CryoBalloon™ Full and Swipe Ablation Systems for Ablation of Human Esophageal Epithelium: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and…
- Clinical Study With Blinatumomab in Pediatric and Adolescent Patients With Relapsed/Refractory B-precursor Acute Lymphoblastic Leukemia: Complete Statistical AnalysisIndependent statistical analysis of Clinical Study With Blinatumomab in Pediatric and Adolescent Patients With Relapsed/Refractory B-precursor Acute Lymphoblastic Leukemia: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety,…
- Clinical Trial of Brentuximab Vedotin in Classical Hodgkin Lymphoma: Complete Statistical AnalysisIndependent statistical analysis of Clinical Trial of Brentuximab Vedotin in Classical Hodgkin Lymphoma: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT03646123).
- Clinical Trial of Standard Versus Goal-Directed Perioperative Fluid Management (GDT) for Patients Undergoing Liver Resection: Complete Statistical AnalysisIndependent statistical analysis of Clinical Trial of Standard Versus Goal-Directed Perioperative Fluid Management (GDT) for Patients Undergoing Liver Resection: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety,…
- Clinical Trial to Assess the Efficacy and Safety of ‘Immuncell-LC’ With Temozolomide in Newly Diagnosed Glioblastoma of Korea: Complete Statistical AnalysisIndependent statistical analysis of Clinical Trial to Assess the Efficacy and Safety of 'Immuncell-LC' With Temozolomide in Newly Diagnosed Glioblastoma of Korea: primary endpoint results, effect estimate with confidence interval, sample-size planning…
- CLL11: A Study of Obinutuzumab (RO5072759 [GA101]) With Chlorambucil in Patients With Previously Untreated Chronic Lymphocytic Leukemia (Stage 1a): Complete Statistical AnalysisIndependent statistical analysis of CLL11: A Study of Obinutuzumab (RO5072759 [GA101]) With Chlorambucil in Patients With Previously Untreated Chronic Lymphocytic Leukemia (Stage 1a): primary endpoint results, effect estimate with confidence interval, sample-size…
- Clodronate With or Without Chemotherapy and/or Hormonal Therapy in Treating Women With Stage I or Stage II Breast Cancer: Complete Statistical AnalysisIndependent statistical analysis of Clodronate With or Without Chemotherapy and/or Hormonal Therapy in Treating Women With Stage I or Stage II Breast Cancer: primary endpoint results, effect estimate with confidence interval, sample-size…
- Clofarabine and Cytarabine in Treating Patients With Acute Myeloid Leukemia With Minimal Residual Disease: Complete Statistical AnalysisIndependent statistical analysis of Clofarabine and Cytarabine in Treating Patients With Acute Myeloid Leukemia With Minimal Residual Disease: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based…
- Clofarabine in Treating Patients With T-Cell or Natural Killer-Cell Non-Hodgkin’s Lymphoma That Has Relapsed or Not Responded to Previous Treatment: Complete Statistical AnalysisIndependent statistical analysis of Clofarabine in Treating Patients With T-Cell or Natural Killer-Cell Non-Hodgkin's Lymphoma That Has Relapsed or Not Responded to Previous Treatment: primary endpoint results, effect estimate with confidence interval,…
- Clofarabine Plus Low-Dose Cytarabine Induction and Decitabine Consolidation in Frontline Acute Myeloid Leukemia (AML) and High-Risk Myelodysplastic Syndrome (MDS): Complete Statistical AnalysisIndependent statistical analysis of Clofarabine Plus Low-Dose Cytarabine Induction and Decitabine Consolidation in Frontline Acute Myeloid Leukemia (AML) and High-Risk Myelodysplastic Syndrome (MDS): primary endpoint results, effect estimate with confidence interval, sample-size…
- Coated VICRYL* Plus Suture Compared to Chinese Silk in Scheduled Breast Cancer Surgery: Complete Statistical AnalysisIndependent statistical analysis of Coated VICRYL* Plus Suture Compared to Chinese Silk in Scheduled Breast Cancer Surgery: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on…
- CodeBreaK 200Independent statistical analysis of CodeBreaK 200, a randomized phase 3 trial comparing AMG 510 (sotorasib) with docetaxel in KRAS G12C-mutated advanced or metastatic NSCLC, including progression-free survival, hazard ratios, confidence intervals, log-rank…